This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.1 (other disorders of branched-chain amino-acid metabolism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | MMA, methylmalonyl-CoA mutase deficiency (mut type), disorders of cobalamin metabolism (cblA, cblB, cblC, cblD types), methylmalonyl-CoA mutase deficiency, methylmalonic aciduria |
| C. Adult onset | Likelihood of first presentation in adulthood low (possible in the cobalamin-responsive form) — mostly presents in the neonatal period to infancy; in mild cobalamin-responsive forms (cblA, cblB), diagnosis in adulthood with intermittent symptoms is possible; sometimes discovered in adulthood as chronic kidney disease. |
| 1. History | First described by Oberholzer and Stokke in 1967 → classification into mut and cbl types in the 1970s → cloning of the MMUT (MUT) gene in the 1990s → identification of MMAA and MMAB in the 2000s → standardization of tandem mass screening. |
| 2. Causes | MUT (MMUT) gene mutations (mut type: cobalamin-unresponsive) or defects in adenosylcobalamin synthesis (cblA/MMAA, cblB/MMAB — cobalamin-responsive). Blocked conversion of methylmalonyl-CoA → succinyl-CoA. |
| 3. Genetics | Autosomal recessive. MMUT (6p21.2), MMAA (4q31.22), MMAB (12q24.11), MMADHC (2q23.2), etc. About 1/50,000–1/100,000 worldwide. The mut0 type is the most severe; cblA and cblB types are cobalamin-responsive. |
| 4. General epidemiology | About 1/50,000–1/100,000 worldwide. High frequency in populations with consanguineous marriage such as Saudi Arabia. Korea: a few cases per year through tandem mass screening. The mut type accounts for about 60–70% of all cases. |
| 5. Pathophysiology | Impaired conversion of methylmalonyl-CoA → succinyl-CoA → accumulation of methylmalonic acid and propionic acid → inhibition of the TCA cycle and urea cycle → ketoacidosis and hyperammonemia; renal toxicity of methylmalonic acid (chronic kidney disease) + basal ganglia damage. |
| 6. Symptoms | Neonatal period: poor feeding, lethargy, vomiting, ketoacidosis, hyperammonemia. Long term: intellectual disability, movement disorders (basal ganglia damage), chronic kidney disease, optic atrophy, pancreatitis, growth failure, metabolic stroke. |
| 7. Signs | Elevated C3-acylcarnitine, markedly increased urinary methylmalonic acid, metabolic ketoacidosis, hyperammonemia, elevated serum creatinine (reduced renal function), basal ganglia signal abnormalities on brain MRI. |
| 8. Screening | Newborn tandem mass screening (elevated C3-acylcarnitine). Differentiation from PA: urine methylmalonic acid measurement is essential. Confirmation of cobalamin response: assessment of response after IM hydroxocobalamin administration. Included in Korean national screening. |
| 9. Diagnosis | Urine organic acids (increased methylmalonic acid and methylcitric acid), blood C3-AC, plasma amino acids (elevated glycine in some), cobalamin supplementation test, NGS of the MUT, MMAA, MMAB and MMADHC genes. Assessment of renal function. |
| 10. Treatment | Cobalamin-responsive form: hydroxocobalamin (IM) + protein restriction. Unresponsive form (mut type): protein restriction, L-carnitine, management of hyperammonemia. Liver transplantation or liver-kidney transplantation (when kidney disease progresses). Kidney protection. |
| 11. Prognosis | The mut0 type has the poorest prognosis (chronic kidney disease, neurologic damage). The cobalamin-responsive form has a relatively favorable prognosis. Chronic kidney disease is the main complication in adult survivors. Some improvement in metabolic control and kidney protection after liver transplantation. |
| 12. Prevention | Newborn tandem mass screening, genetic counseling, PGT-M. Affected individuals: emergency protocol for catabolic stress, regular IM cobalamin administration in the cobalamin-responsive form, vaccination against infections, regular monitoring of renal function. |
| 13. References | Oberholzer VG et al. Methylmalonic aciduria: an inborn error of metabolism leading to chronic metabolic acidosis. Arch Dis Child. 1967;42:492-504 … and 9 other papers |
Methylmalonic acidemia (MMA) was first described in 1967 when Oberholzer et al. and Stokke et al. in the UK independently reported massive urinary excretion of methylmalonic acid in newborns with metabolic ketoacidosis and hyperglycinemia. At the time it was named "methylmalonic aciduria," and it later also came to be called methylmalonic acidemia to emphasize the accumulation of methylmalonic acid in the blood.
In the 1970s, Rosenberg et al. confirmed through cell complementation analysis that MMA is genetically heterogeneous. A classification system was established into the mut type, caused by deficiency of the methylmalonyl-CoA mutase (MCM) enzyme itself, and the cbl type (cobalamin cofactor deficiency type), caused by defects in the synthesis pathway of adenosylcobalamin (AdoCbl), the cofactor of this enzyme. The mut type is divided into two subtypes, unresponsive (mut0) or partially responsive (mut-) to cobalamin administration, and the cbl type is subdivided into cblA (MMAA gene defect), cblB (MMAB gene defect), cblD (MMADHC gene defect) and others.
In the field of molecular genetics, the MMUT (formerly MUT) gene encoding methylmalonyl-CoA mutase was cloned at 6p21.2 in the 1990s, and genes such as MMAA (4q31.22), MMAB (12q24.11) and MMADHC (2q23.2) were subsequently identified one after another. With the standardization of tandem mass screening in the early 2000s, early diagnosis in the neonatal period based on elevated C3-acylcarnitine (propionylcarnitine) became possible, and confirmation of cobalamin responsiveness was established as a key step in clinical management. Liver transplantation has been established as a treatment option for patients with mut-type MMA since the 1990s, and combined liver-kidney transplantation is also performed when renal complications are severe.
Methylmalonic acidemia is caused by functional deficiency of methylmalonyl-CoA mutase (MCM), which converts methylmalonyl-CoA derived from propionyl-CoA to succinyl-CoA, or by defects in the synthesis of adenosylcobalamin (AdoCbl), the cofactor of this enzyme. MCM is an enzyme located in mitochondria and requires AdoCbl, the active form of vitamin B12 (cobalamin), as a cofactor.
MMA is classified by genetic cause as follows. (1) mut type (MMUT gene defect): the most common form, accounting for about 60–70% of all MMA. The MMUT gene is located at 6p21.2 and encodes the MCM protein. It is divided into the mut0 subtype (complete loss of enzyme function) and the mut- subtype (residual enzyme activity present); mut0 is more severe and does not respond to cobalamin administration. (2) cblA type (MMAA gene defect): the MMAA gene (4q31.22) encodes a protein required for the adenosylation of cobalamin within mitochondria. The cblA type is a cobalamin-responsive form that responds to hydroxocobalamin (OHCbl) administration and has a relatively favorable prognosis. (3) cblB type (MMAB gene defect): the MMAB gene (12q24.11) encodes adenosylcobamide synthase; it is similar to the cblA type but somewhat less cobalamin-responsive. (4) cblD type isolated MMA (MMADHC gene defect): the MMADHC gene (2q23.2) is involved in cobalamin transport and processing; some mutations cause isolated MMA and others cause an MMA + homocystinemia (combined cblD) phenotype. (5) cblC, cblF, cblJ and cblX types: these forms also inhibit methylcobalamin synthesis, so MMA and homocystinemia occur in combination, and they are strictly distinguished from isolated MMA. Meanwhile, transient methylmalonic aciduria due to inadequate cobalamin intake (dietary cause) or maternal cobalamin deficiency also needs to be differentiated.
Methylmalonic acidemia follows autosomal recessive inheritance for all causative genotypes. The locations and characteristics of the main genes are as follows. MMUT (6p21.2): encodes the MCM enzyme. Hundreds of pathogenic variants reported. Founder mutations exist in certain ethnic groups (e.g., p.P86L in certain European populations). Mutation location is important for distinguishing the mut0/mut- subtypes. MMAA (4q31.22): cause of the cblA type. Founder mutations reported in some populations. MMAB (12q24.11): cause of the cblB type. MMADHC (2q23.2): an unusual gene in which the location of a specific variant determines an isolated MMA or MMA + homocystinemia phenotype.
As for genotype-phenotype correlation, mut0 variants (complete loss of function) > mut- variants (partial loss of function) are associated with severe phenotypes, in that order. The cblA and cblB types are often cobalamin-responsive and have a relatively favorable prognosis. The worldwide prevalence is estimated at about 1/50,000–1/100,000, and MMA, together with other organic acidemias such as PA and IVA, is a major target of newborn tandem mass screening. Studies of the mutation spectrum in Korean and East Asian populations are accumulating, but most variants are reported as private variants. Heterozygous carriers are asymptomatic.
Based on newborn tandem mass screening data, the worldwide prevalence of methylmalonic acidemia is estimated at about 1/50,000–1/100,000. This is relatively common among organic acidemias. Regionally, the prevalence is markedly higher in countries where consanguineous marriage is frequent, such as Saudi Arabia, Iran and Turkey. In Saudi Arabia, the prevalence of MMA has been reported at about 1/2,000–5,000. The sex distribution is equal.
The frequency of each causative genotype varies by population, but overall the mut type (MMUT defect) accounts for about 60–70% of all isolated MMA, the cblA type about 20–25% and the cblB type about 10–15%. In Korea, several patients with MMA have been detected early each year through tandem mass newborn screening since 2006, and MMA is differentiated, together with PA, as a main cause of elevated C3-acylcarnitine. The number of registered patients in Korea is estimated at tens to hundreds, and cobalamin-responsive patients show a relatively favorable course after hydroxocobalamin treatment. Before tandem mass screening, many patients died of acute metabolic crises or suffered serious neurologic damage, but prognosis is now improving thanks to the early diagnosis system.
The core pathophysiology of methylmalonic acidemia is intramitochondrial accumulation of methylmalonyl-CoA due to MCM deficiency (or defective AdoCbl synthesis) and a secondary toxic cascade. Methylmalonyl-CoA should normally be converted to succinyl-CoA and supplied to the TCA cycle, but in MMA this conversion is blocked, and methylmalonyl-CoA is hydrolyzed to methylmalonic acid (MMA), which accumulates in the blood, tissues and urine.
TCA cycle inhibition: methylmalonic acid directly inhibits key enzymes of the TCA cycle (succinate dehydrogenase, alpha-ketoglutarate dehydrogenase, pyruvate dehydrogenase), reducing mitochondrial ATP production. Urea cycle inhibition: by the same mechanism as in PA, N-acetylglutamate (NAG) synthesis is inhibited, causing hyperammonemia. Renal toxicity: sustained exposure to high concentrations of methylmalonic acid causes progressive chronic kidney disease (CKD) through direct toxicity to proximal tubular cells and oxidative stress. This is one of the most serious long-term complications of MMA, and dialysis-dependent end-stage renal failure develops in many adult survivors of the mut0 type. Selective basal ganglia damage: the combined toxicity of methylmalonic acid and propionic acid selectively damages the striatum of the basal ganglia, which manifests as dyskinesia, dystonia and metabolic stroke. Oxidative stress: methylmalonic acid inhibits mitochondrial complex I, increasing production of reactive oxygen species (ROS), which causes oxidative damage to renal, brain and optic nerve cells. Optic atrophy occurs as a result of this oxidative damage.
Acute neonatal presentation: the infant appears normal at birth, but within 24–96 hours after feeding begins, poor feeding, lethargy, hypotonia, vomiting and irritability appear and rapidly worsen into metabolic ketoacidosis, hyperammonemia and hypoglycemia. Without treatment, death in the neonatal period can occur from seizures, cerebral edema, coma and cardiopulmonary failure. The mut0 type shows the most abrupt presentation. Symptoms of the cobalamin-responsive forms (cblA, cblB) are generally less abrupt, and some are first diagnosed in infancy or childhood with an episode of metabolic crisis.
Long-term complications: (1) Neurologic complications: intellectual disability, developmental delay, dyskinesia and dystonia due to basal ganglia damage, metabolic stroke — mainly involving the basal ganglia and internal capsule and presenting as sudden movement disorders. (2) Chronic kidney disease (CKD): the most important long-term complication of MMA, progressing to end-stage renal disease (ESRD) in the 10s–30s in many patients with the mut type. Preservation of renal function is the key goal of long-term management. (3) Optic atrophy: progressive visual decline and color vision abnormalities due to oxidative damage. (4) Growth failure, osteoporosis, pancreatitis. (5) Structural brain changes such as white matter signal abnormalities and cerebellar atrophy. These complications can progress slowly from chronic methylmalonic acid toxicity even without metabolic crises.
Biochemical test findings: (1) Urine organic acid analysis (GC-MS): a marked increase in methylmalonic acid is the most specific diagnostic marker of MMA. Only trace amounts are detected in normal urine, but in patients with MMA it rises to tens to hundreds of mmol/mol Cr. Methylcitric acid and 3-hydroxypropionic acid are also increased, but relatively less than in PA. (2) Tandem mass screening: elevated C3-acylcarnitine (propionylcarnitine). Because it is the same marker as in PA, differentiation is by urine organic acid analysis. (3) Quantification of blood methylmalonic acid (plasma MMA measurement): used for diagnosis and treatment monitoring. (4) Plasma amino acids: elevated glycine is observed in some, but less consistently than in PA. (5) Metabolic ketoacidosis, hyperammonemia and hypoglycemia appear in the acute phase.
Cobalamin response test: when hydroxocobalamin (OHCbl) 1 mg/day is given by intramuscular injection for 1–2 weeks, urinary methylmalonic acid excretion decreases markedly (>50% reduction) in cobalamin-responsive forms (cblA, some cblB). The mut type does not respond. This test is essential for deciding the treatment strategy. Renal function indicators: renal function is monitored with serum creatinine, glomerular filtration rate (eGFR), urine proteinuria and others. Brain MRI: symmetric T2 hyperintensity and DWI abnormalities of the basal ganglia (putamen, caudate) and internal capsule (metabolic stroke), white matter signal abnormalities, cerebellar atrophy and others may be observed.
Methylmalonic acidemia is a core target disease of newborn tandem mass screening. In Korea, MMA has been included in national newborn screening together with PA since 2006. Elevated C3-acylcarnitine (propionylcarnitine) and an increased C3/C2 ratio are used as screening markers. However, because elevated C3-AC occurs in both PA and MMA, when screening is positive it is essential to differentiate the two diseases by confirming methylmalonic acid excretion with urine organic acid analysis.
Because secondary methylmalonic aciduria can occur in newborns born to cobalamin-deficient mothers or in breastfed newborns, producing false-positive screening results, checking serum cobalamin levels and maternal cobalamin status helps in differentiation. Screen-positive newborns are immediately referred to a specialized metabolic disease clinic for prompt confirmatory testing and cobalamin response testing, and if severe mut type is confirmed, dietary treatment is started as soon as possible. When there is a family history, fetal diagnosis is also possible through prenatal molecular genetic testing (MMUT, MMAA, MMAB genes) or measurement of amniotic fluid methylmalonic acid.
Methylmalonic acidemia is confirmed in the following steps. (1) Urine organic acid analysis (GC-MS): confirmation of a marked increase in methylmalonic acid is central to the diagnosis of MMA. (2) Plasma/urine C3-acylcarnitine: elevated. Common to PA, but differentiation is possible by methylmalonic acid excretion. (3) Cobalamin response test: after intramuscular hydroxocobalamin injection, check whether urinary MMA decreases. If a cobalamin-responsive form is confirmed, long-term cobalamin treatment is applied. (4) MCM enzyme activity measurement: MCM enzyme activity is measured in leukocytes or fibroblasts. Activity is extremely reduced in the mut0 type. (5) Molecular genetic testing: NGS panel testing of the MMUT, MMAA, MMAB and MMADHC genes. Genotype confirmation is essential for subtype classification, prediction of cobalamin response and family testing. (6) Renal function assessment: serum creatinine, eGFR, quantitative urine protein. Renal function of patients with MMA should be monitored regularly from diagnosis. (7) Brain MRI and ophthalmologic examination: assessment of neurologic complications. Fundus examination and OCT to check for optic atrophy. (8) Differential diagnosis: propionic acidemia (normal urinary MMA), cobalamin deficiency (dietary or maternal cause), methylmalonic acidemia + homocystinemia (cblC, cblD types).
The treatment strategy for methylmalonic acidemia differs depending on cobalamin responsiveness.
Treatment of cobalamin-responsive forms (cblA, some cblB): intramuscular injection of hydroxocobalamin (OHCbl) is the core of treatment. OHCbl is preferred over cyanocobalamin. The maintenance dose is usually 1 mg/week to 1 mg/day IM and requires individual adjustment. A balanced diet containing adequate protein is also maintained, and when the cobalamin response is sufficient, the intensity of protein restriction can be reduced. L-carnitine supplementation (50–100 mg/kg/day) to prevent secondary carnitine deficiency.
Treatment of the cobalamin-unresponsive form (mut0 type): (1) Protein-restricted special diet (formula restricted in isoleucine, valine, threonine and methionine, or a low-protein diet). (2) L-carnitine supplementation. (3) During acute metabolic crisis, high-energy glucose and insulin administration, temporary suspension of protein, and management of hyperammonemia (N-carbamylglutamate, sodium benzoate). (4) Kidney protection: an angiotensin-converting enzyme inhibitor (ACE inhibitor) or ARB is given early when proteinuria develops, in the expectation of a kidney-protective effect. Adequate fluid intake is maintained. (5) Liver transplantation: in MMA with recurrent metabolic crises or poor control, blood MMA concentrations decrease by 50–90% after liver transplantation and acute metabolic crises decrease markedly. However, because MCM deficiency in extrahepatic tissues (kidney, brain) is not resolved, renal complications may continue to progress. When end-stage renal failure is reached, combined liver-kidney transplantation is performed. Because stabilization of renal function after transplantation has been reported, preemptive liver-kidney transplantation is sometimes considered.
The prognosis of methylmalonic acidemia varies greatly with genotype and adequacy of treatment. The mut0 type has the poorest prognosis of all MMA, with recurrent acute metabolic crises, dyskinesia due to basal ganglia damage and progressive chronic kidney disease as the main causes of morbidity. Renal decline often progresses slowly and asymptomatically and then leads to dialysis-dependent end-stage renal failure in the 10s–30s. Renal impairment in patients with the mut type is known to be difficult to prevent completely even with good treatment. The cblA and cblB types (cobalamin-responsive) have good metabolic control with OHCbl treatment, a markedly lower incidence of neurologic and renal complications, and a relatively good prognosis.
After liver transplantation, the frequency of acute metabolic crises falls, blood MMA concentrations decrease markedly and quality of life improves. However, reversal of neurologic damage that has already occurred is difficult to expect. Combined liver-kidney transplantation is reported to restore renal function as well and to contribute to improved long-term prognosis. Overall, early diagnosis through newborn tandem mass screening, optimal treatment according to cobalamin responsiveness, and regular renal and neurologic monitoring are key to improving the long-term prognosis of patients with MMA.
Primary prevention of methylmalonic acidemia is achieved through genetic counseling and prenatal/preimplantation genetic testing. Couples who have a child with MMA have a 25% risk of an affected child in each pregnancy, and affected fetuses can be identified in advance through PGT-M or prenatal DNA testing. Measurement of methylmalonic acid in amniotic fluid is also one method of prenatal diagnosis.
As secondary prevention in affected patients, the key is to perform early confirmation and cobalamin response testing promptly after newborn tandem mass screening and to start optimal treatment. Because catabolic stress (fever, infection, surgery, childbirth) is a major trigger of acute metabolic crises, an emergency protocol (temporary protein restriction, high-energy administration) is taught in advance and carried out immediately in an emergency. To prevent infection, vaccinations such as pneumococcal, influenza and rotavirus are given thoroughly. For kidney protection, early use of RAAS blockers (ACE inhibitor or ARB), adequate fluid intake and avoidance of nephrotoxins (contrast agent, NSAIDs, etc.) are important. Systematic management that detects and addresses complications early through regular follow-up of renal function (eGFR, proteinuria), neurodevelopment, vision and brain MRI is decisive for long-term prognosis.